<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03875729</url>
  </required_header>
  <id_info>
    <org_study_id>PRV-031-001</org_study_id>
    <nct_id>NCT03875729</nct_id>
  </id_info>
  <brief_title>Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab</brief_title>
  <acronym>PROTECT</acronym>
  <official_title>Phase 3 Randomized Double-Blind Multinational Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab, a Humanized FcR Non-Binding Anti-CD3 Monoclonal Antibody, in Children and Adolescents With Newly Diagnosed Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Provention Bio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Provention Bio, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether teplizumab slows the loss of β cells and&#xD;
      preserves β cell function in children and adolescent 8-17 years old who have been diagnosed&#xD;
      with T1D in the previous 6 weeks..&#xD;
&#xD;
      Subjects will receive two courses of either teplizumab or placebo treatment 6 months apart.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, multi-center&#xD;
      study to evaluate the efficacy and safety of teplizumab, a humanized, anti-CD3 monoclonal&#xD;
      antibody, in children and adolescents ages 8 through 17 recently diagnosed with type 1&#xD;
      diabetes (within 6 weeks of diagnosis). Approximately 300 participants will be randomized at&#xD;
      a ratio of 2:1 to either the teplizumab group or the placebo group.&#xD;
&#xD;
      Teplizumab or matching placebo will be administered in two courses 6 months apart. Each&#xD;
      course of treatment will include daily infusions for 12 days. The total study duration for&#xD;
      each participant will be up to 86 weeks.&#xD;
&#xD;
      The primary objective is to determine whether two courses of teplizumab administered 6 months&#xD;
      apart slows the loss of β cells and preserves β cell function over 18 months (78 weeks) in&#xD;
      children and adolescents 8-17 years old who have been diagnosed with T1D in the previous 6&#xD;
      weeks.&#xD;
&#xD;
      The secondary objectives are to evaluate improvements in key clinical parameters of diabetes&#xD;
      management, to determine the safety and tolerability of teplizumab, and to evaluate the&#xD;
      pharmacokinetics (PK) and immunogenicity of teplizumab&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 5, 2019</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase 3, randomized, double-blind, placebo-controlled, multinational, multicenter study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The area under the time-concentration curve (AUC) of C-peptide after a mixed meal tolerance test (MMTT) at Week 78</measure>
    <time_frame>Week 78</time_frame>
    <description>Clinical Endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exogenous insulin use</measure>
    <time_frame>Week 78</time_frame>
    <description>Clinical Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c levels</measure>
    <time_frame>Week 78</time_frame>
    <description>Clinical Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in glycemic target range</measure>
    <time_frame>Week 78</time_frame>
    <description>Clinical Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically important hypoglycemic episodes</measure>
    <time_frame>Week 78</time_frame>
    <description>Clinical Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), and serious adverse events (SAEs)</measure>
    <time_frame>Up to Week 52 and Week 78</time_frame>
    <description>Safety Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Teplizumab serum concentrations</measure>
    <time_frame>78 Week</time_frame>
    <description>PK Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and titers of anti-teplizumab antibodies after treatment courses</measure>
    <time_frame>78 Week</time_frame>
    <description>Immunogenicity Endpoint</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>teplizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sterile solution for injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sterile solution for injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>teplizumab</intervention_name>
    <description>Treatment</description>
    <arm_group_label>teplizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Control</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Is 8 to 17 years of age, inclusive, at the time of randomization/initiation of study&#xD;
             drug administration.&#xD;
&#xD;
          2. Has received a diagnosis of T1D according to the criteria from the American Diabetes&#xD;
             Association.&#xD;
&#xD;
          3. Is able to be randomized and initiate study drug within 6 weeks (42 days) of the&#xD;
             formal T1D diagnosis.&#xD;
&#xD;
          4. Has a peak stimulated C-peptide of ≥0.2 pmol/mL from a mixed meal tolerance test&#xD;
             (MMTT) at screening.&#xD;
&#xD;
          5. Has a positive result on testing for T1D-related autoantibodies.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has any autoimmune disease other than T1D with the exception of stable thyroid or&#xD;
             celiac disease.&#xD;
&#xD;
          2. Has an active infection and/or fever.&#xD;
&#xD;
          3. Has a history of or serologic evidence at screening of current or past infection with&#xD;
             human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus&#xD;
             (HCV).&#xD;
&#xD;
          4. An individual who has a medical, psychological or social condition that, in the&#xD;
             opinion of the Principal Investigator, would interfere with safe and proper completion&#xD;
             of the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Provention Bio, MD</last_name>
    <role>Study Director</role>
    <affiliation>Provention Bio, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rady Children's Hospital-San Diego (Site 004)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center (Site 001)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research, Inc. (Site 002)</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado-Barbara Davis Center for Childhood Diabetes (Site 005)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University of Medicine (Site 020)</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UF Clinical and Translation Research Building (Site 015)</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Specialty Care-Endocrinology (Site 047)</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Health System (Site 028)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>All Children's Hospital-Johns Hopkins Medicine (Site 048)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida Diabetes and Endocrinology Center (Site 011)</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Diabetes Associates (Site 009)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbus Regional Research Institute (Site 006)</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Children's Endocrinology (Site 052)</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>82712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Diabetes and Osteoporosis Center (Site 007)</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center (Site 017)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Hospital and Riley Hospital for Children (Site 014)</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U. Iowa Children's Hospital (Site 023)</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital Diabetes &amp; Endocrine Associates (Site 029)</name>
      <address>
        <city>Camp Springs</city>
        <state>Maryland</state>
        <zip>20746</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baystate Pediatric Endocrinology &amp; Diabetes (Site 040)</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U. Minnesota Health Clinical Research Unit (Site 031)</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospitals &amp; Clinics (Site 026)</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine (Site 018)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women and Children's Hospital of Buffalo (Site 010)</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Hospitals Children's Specialty Clinic (Site 038)</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies &amp; Children's Hospital (Site 049)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic (Site 051)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrinology Service Northwest, LLC (Site 034)</name>
      <address>
        <city>Bend</city>
        <state>Oregon</state>
        <zip>97702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital of Philadelphia - Endocrinology (Site 021)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Diabetes and Thyroiid Clinical (Site 013)</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AM Diabetes &amp; Endocrinology Center (Site 008)</name>
      <address>
        <city>Bartlett</city>
        <state>Tennessee</state>
        <zip>38133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center (Site 024)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center Dallas (Site 033)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benaroya Research Institute at Virginia Mason (Site 016)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MultiCare Institute for Research &amp; Innovation (Site 003)</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Brussel - Campus Jette (Site 202)</name>
      <address>
        <city>Bruxelles</city>
        <state>Brussels Capital Region</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent (Site 206)</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU UCL Namur, site Clinique Sainte-Elisabeth (Site 205)</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alberta Diabetes Institute Clinical Research Unit Li Ka Shing Centre for Health Research Innovation (Site 103)</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2J3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BC Diabetes (Site 102)</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Children's Hospital-McGill (Site 101)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice v Motole (Site 301)</name>
      <address>
        <city>Praha 5</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux Pediatriques de Nice CHU-Lenval service de diabetologie et d'endocrinologia (Site 508)</name>
      <address>
        <city>Nice</city>
        <state>Alpes-Maritimes</state>
        <zip>6200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hopital de la Timone-Hopital d'Enfants (Site 512)</name>
      <address>
        <city>Marseille</city>
        <state>Bouces-du-Rhone</state>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU DIJON hopital d'enfant (Site 504)</name>
      <address>
        <city>Dijon Cedex</city>
        <state>cote-d'Or</state>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Necker Enfants Malades (site 502)</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-France</state>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional (CHR) d'Orleans-Service de pediatrie (Site 513)</name>
      <address>
        <city>Orleans</city>
        <state>Loiret</state>
        <zip>45100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe hospitalier Est-Hopital Femme, Mere, Enfant (Site 509)</name>
      <address>
        <city>Bron Cedex</city>
        <state>Rhone</state>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de Pau (Site 501)</name>
      <address>
        <city>Pau cedex</city>
        <zip>64046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg (Site 603)</name>
      <address>
        <city>Freiburg im Breisgau</city>
        <state>Baden-Wurttemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg (Site 608)</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wurtternberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Augsburg (Site 606)</name>
      <address>
        <city>Augsburg</city>
        <state>Bayem</state>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Klinikum Bethel Kinderklinik (Site 602)</name>
      <address>
        <city>Bielefeld</city>
        <state>Nordrhein-Westfalen</state>
        <zip>33617</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Carl Gustav Carus (Site 601)</name>
      <address>
        <city>Dresden</city>
        <state>Sachson</state>
        <zip>-1307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinderkrankenhaus Auf Der Bult (Site 604)</name>
      <address>
        <city>Hannover</city>
        <zip>30173</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Békés Megyei Központi Kórház Pándy Kálmán Tagkórház ( Site 705)</name>
      <address>
        <city>Gyula</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu (Site 804)</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>01-184</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut &quot;Pomnik - Centrum Zdrowia Dziecka&quot; (Site 801)</name>
      <address>
        <city>Warszawa</city>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Diabetologii Sp. z o.o. (Site 802)</name>
      <address>
        <city>Warszawa</city>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne (Site 803)</name>
      <address>
        <city>Warszawa</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwick Park Hospital - Paediatrics (site 904)</name>
      <address>
        <city>London</city>
        <state>City Of London</state>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiff and Vale NHS Trust - University Hospital of Wales (Site 902)</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheffield Children's NHS Foundation Trust Western Bank (Site 903)</name>
      <address>
        <city>Sheffield</city>
        <zip>s10 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 13, 2019</study_first_submitted>
  <study_first_submitted_qc>March 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2019</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T1D, type 1 diabetes, recent-onset T1D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

